Home›Stocks›DFTX

DFTX — structural market context

Definium Therapeutics, Inc. Co

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 16. Each line shows the earlier value, the later value and their dates.

Price

Close $32.10 (Oct 16) vs $34.26 (Oct 15): −6.30%.

Volume

0.86× its 20-session average (2.3M) on Oct 16.

Includes pre- and post-market trading.

Short interest

Short interest 11.3M shares (settlement Sep 30) vs 11.8M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 8 days with fails, largest 1K shares on Sep 18.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 2 days with fails, largest 313 shares on Sep 8.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

DFTX short interest & days to cover

SHARES SHORT
11.3M
% OF FLOAT
—
DAYS TO COVER
4.9
CHANGE VS PRIOR
-3.7%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (17d ago)

DFTX fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-30 · 17d206$38.21
2026-09-25 · 22d263$36.73
2026-09-23 · 24d254$40.32

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

DFTX insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 6 sales

InsiderTypeSharesValueFiled
Sullivan Mark · officer: Chief Legal OfficerSell (S)14K$514K2026-09-29
Roberts Brandi · officer: Chief Financial OfficerSell (S)3K$123K2026-09-29
Karlin Daniel · director, officer: Chief Medical OfficerSell (S)11K$397K2026-09-29
Barrow Robert · director, officer: Chief Executive OfficerSell (S)32K$1.2M2026-09-29
Wiley Matthew T. · officer: Chief Commercial OfficerSell (S)3K$113K2026-09-29

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

DFTX analyst ratings

FirmActionRatingPublished
Canaccord Genuityprice_target—2026-09-15
H.C. WainwrightholdBuy2026-09-15
UBSprice_target—2026-09-15
UBSholdBuy2026-09-15
Robert W. Bairdprice_target—2026-09-15

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

Are insiders buying DFTX?
In the last 12 months of SEC Form 4 filings, DFTX recorded 0 insider purchases and 6 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about DFTX?
The most recent action: Canaccord Genuity price_target on 2026-09-15. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell DFTX?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with D

DAR · DARLING INGREDIENTS INC.DASH · DoorDash, Inc.DDOG · Datadog, Inc.DFH · Dream Finders Homes, Inc.DGICA · Donegal Group, Inc.DH · Definitive Healthcare Corp. ClAll D →

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.